← 홈

Antibody · 고형암 (전체)

287개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 287개
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 6상태 RECRUITING
AntibodystaleAravive, Inc.Phase 2

Batiraxcept (Batiraxcept)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 11%임상시험 5상태 DISCONTINUED
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Boserolimab (Boserolimab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
효능 ORR 7.1%임상시험 5상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED
AntibodystaleEisai Inc.Phase 2

Farletuzumab ecteribulin (Farletuzumab ecteribulin)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+2
효능 ORR 20%임상시험 4상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+4
효능 ORR 28.8%임상시험 4상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
AntibodystaleThe First Affiliated Hospital o…Phase 2

Adebellizumab (Adebellizumab)

Resectable Lung Non-Small Cell Carcinoma · Resectable Lung Non-Small Cell Carcinoma

#ResectableLungNon-SmallCellCarci#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleGilead SciencesPhase 1

Andecaliximab (Andecaliximab)

Gastric Adenocarcinoma · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase1#항체#면역항체+3
효능 ORR 9.7%임상시험 3상태 DISCONTINUED
AntibodystaleRochePreclinical

atezolizumab (Tecentriq, Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization)

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Inter… · Advanced Hepatocellular Carcinoma (HCC),

#AdvancedHepatocellularCarcinomaH#Antibody#Preclinical#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleRochePhase 2

bevacizumab (Avastin, Avastin (bevacizumab))

Recurrent Respiratory Papillomatosis · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 3상태 ACTIVE
AntibodystaleAVEO Pharmaceuticals, Inc.Phase 2

Ficlatuzumab (Ficlatuzumab)

Head and Neck Basaloid Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma · Carcinoma, Squamous Cell of Head and Nec

#CarcinomaSquamousCellofHeadandNe#Antibody#Phase2#항체#면역항체+4
효능 ORR 1%임상시험 3상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

Niraparib + Ipilimumab (Niraparib + Ipilimumab)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 7.7%임상시험 3상태 ACTIVE
AntibodystaleRochePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+carboplatin±bevacizumab)

Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleGenentech, Inc.Phase 1

XmAb24306 (XmAb24306)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 3상태 ACTIVE
AntibodystaleRochePreclinical

atezolizumab (Tecentriq, atezolizumab plus bevacizumab)

Hepatocellular Carcinoma; Hepatic Portal Vein Tumor Invasion · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#Antibody#Preclinical#항체#면역항체+4
효능 ORR 49.3%임상시험 3상태 ACTIVE
AntibodystaleDwight OwenPhase 1

Adenosine A2B Receptor Antagonist PBF-1129 (Adenosine A2B Receptor Antagonist PBF-1129)

Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Lung Non-Small Cell Carcinoma

#MetastaticLungNon-SmallCellCarci#Antibody#Phase1#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleJiangsu HengruiPhase 2

Albumin-paclitaxel + carboplatin + apatinib + camrelizumab (Albumin-paclitaxel + carboplatin + apatinib + camrelizumab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleRocheApproved

atezolizumab (Tecentriq, Atezolizumab Injection [Tecentriq])

Hepatocellular Carcinoma · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Approved#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE

4 / 15 페이지

← 이전다음 →